---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091425"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T09:59:01.140415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025

## Summary
- Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.
- Non-dilutive agreement with Cell Ready provides ~$19M cash and reduces annual operating expenses by ~$11M.
- Appointed Juan Vera as CEO and Monic Stuart as CMO to lead restructuring and clinical advancement.
- NIH awarded $2M SBIR grant for MT-401 AML program; EMA granted Orphan Drug Designation for MT-401.
- First lymphoma patient dosed with MT-601 in Phase 1 APOLLO trial with no treatment-related adverse events.

## SEC filing metadata
- accession: 0001104659-23-091425
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/0001104659-23-091425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/tm2323634d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091425
- JSON: https://secwatch.observer/filing/0001104659-23-091425.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091425.txt

## Key facts
- Earnings Releases
  Marker Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/0001104659-23-091425-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.